Parathyroid Hormone has 6 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Droperidol, Calcium Chloride, Calcium Chloride Dihydrate. Patients taking Parathyroid Hormone should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 1
- Moderate
- 5
Major (1)
- Parathyroid Hormone + Droperidol— Supraphysiological use may induce hypokalemia or hypomagnesemia, precipitating QT prolongation with droperidol.
Moderate (5)
- Parathyroid Hormone + Calcium Chloride— Increases risk of hypercalcemia when used concomitantly. Increase frequency of calcium concentration monitoring.
- Parathyroid Hormone + Calcium Chloride Dihydrate— Increases risk of hypercalcemia. Increase frequency of calcium concentration monitoring.
- Parathyroid Hormone + Metyrapone— May affect the results of the metyrapone test. Consider withdrawing if possible before testing.
- Parathyroid Hormone + Ropinirole— Higher doses of estrogens reduce clearance of ropinirole; starting or stopping HRT may require dose adjustment.
- Parathyroid Hormone + Ropinirole Hydrochloride— Higher doses of estrogens reduce ropinirole clearance; starting or stopping HRT may require ropinirole dose adjustment.